SNOA logo

SONOMA PHARMACEUTICALS INC

SNOANASDAQ
πŸ† #5129 by market capEarnings Nov 2US Equity
$1.25β–Ό $0.01 (βˆ’1.19%)
πŸŒ™ After hours$1.25β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track SNOA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.2%
7dβ–Ό 4.2%
14dβ–Ό 2.7%
30dβ–Ό 4.6%
ytdβ–Ό 65.3%
1yβ–Ό 69.0%
🏦Market Cap
$6M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+47.0%
High Growth
πŸ“ŠGross Margin
38.9%
Healthy
πŸ’΅FCF Margin
4.8%
Moderate
βš–οΈP/S Ratio
0.3x
Cheap
Otter Score
52
Weak

Trading Snapshot

Day Range
$1.23 – $1.26
52-Week Range
$0.85 – $4.60
Volume
$2.32B
Avg Volume
$1.97B
Shares Outstanding
4.8M
Next Earnings
Dec 1, 2026

Fundamentals Snapshot

Annual Revenue
$20M
Last Q Revenue
$6M
P/E Ratio
β€”
P/S Ratio
0.3x
EPS (TTM)
$-1.22
Dividend Yield
β€”
Dilution (1yr)
+124.5%

Why Investors Own SNOA

  • βœ“High-growth profile β€” revenue up -6.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 73% gross margin and 14% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SNOA logo

SONOMA PHARMACEUTICALS INC

SNOA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$20Mβ–² +36.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
38.0%β–Ό βˆ’0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$2Mβ–Ό βˆ’33.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$4Mβ–² +2355.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.8Mβ–² +124.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About SONOMA PHARMACEUTICALS INC

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
52/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy3
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Defense WorldΒ·4d ago

Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV)

Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the stre

Defense WorldΒ·21d ago

Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysis

Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based o

AccesswireΒ·Aug 6

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared to the prior-year quarter Gross margin expanded to 40% as operating expenses remained stable FDA clearance and new glob

BenzingaΒ·Aug 6

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) on Thursday posted a first-quarter loss of 9 cents per share compared to a loss of 76 cents a year ago.

AccesswireΒ·Jun 30

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k) clearance from t